Applied Dna Stock News

ATGE, ALGN, and APDN have been added to the Zacks Rank #5 (Strong Sell) List on February 15, 2022

Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -231.58% and 2.62%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc

Applied DNA Sciences press release (APDN): Q1 GAAP EPS of -$0.63.Revenue of $4.17M (+157.4% Y/Y).Shares -1%.

Applied DNA Sciences, Inc.'s (APDN) CEO James Hayward on Q1 2022 Results - Earnings Call Transcript

Applied DNA Sciences (NASDAQ:APDN) is scheduled to announce Q1 earnings results on Thursday, February 10th, after market close.The consensus EPS Estimate is -$0.18 (+79.5% Y/Y) and…

Napco (NSSC) delivered earnings and revenue surprises of -66.67% and 6.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Applied DNA Sciences (APDN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19Testing--Applied DNA to report FQ1'22 financial results after market close on February 10, 2022, and host an investor call at 4:30 pm ET.

Applied DNA Sciences (APDN) said that its subsidiary, Applied DNA Clinical Labs ((ADCL)) is ready to launch its Linea 1.0 COVID-19 Assay for the identification of mutations indicating

Applied DNA Sciences <> submitted a request to the U.S

Applied Dna Sciences Inc (APDN) shares closed 5.8% lower than its previous 52 week low, giving the company a market cap of $34M. The stock is currently down 10.2% year-to-date, down 15.5% over the past 12 months, and down 94.0% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 67.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Industrials industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -130.3% The company's stock price performance over the past 12 months lags the peer average by -146.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Applied DNA Sciences (NASDAQ:APDN) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, Applied DNA Sciences, Inc. provides proprietary DNA-embedded biotechnology security solutions, using non-human DNA, that verify authenticity and protect corporate and government agencies from counterfeiting, []

Applied DNA Sciences (NASDAQ:APDN) had its price objective cut by HC Wainwright from $11.00 to $8.00 in a report issued on Friday, The Fly reports. They currently have a buy rating on the technology companys stock. Separately, Zacks Investment Research downgraded shares of Applied DNA Sciences from a hold rating to a sell rating in []